ExpreS2ion to present in investor and R&D events in March
Hørsholm, Denmark, 15 April 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate in investor and R&D events during March.
By attending relevant industry and investor events, the company aims to increase the awareness of its technology platform and its exciting development pipeline. More information on each event and how to register is found below and on the Company’s website.
17 April 2024 | Aktiespararna Life Science Investor Conference
16:25 CET | Virtual
Join us for a live update from our CEO, Bent Frandsen, at Aktiespararna’s Life Science Investor Day in Stockholm. The event can be streamed through Aktiespararna’s YouTube channel or directly from their website at aktiespararna.se/tv/live. To register for the event, please follow the provided link.
23-25 April 2024 | Immune-Oncology Summit Europe 2024
London, UK
We look forward to presenting at the eighth annual Immuno-Oncology Summit Europe where we will contribute to the Cambridge Healthtech Institute's Inaugural program "Therapeutic Cancer Vaccines, Immunological Advances for Cancer Treatment." On April 23 at 4:30pm, as part of the Peptide-Based Vaccines track, ExpreS2ion CSO Farshad Guirakhoo will present "Preclinical Proof of Concept Studies of a Novel Human HER-2 Virus Like Particle as a Vaccine Candidate for Human Breast Cancers." To schedule a meeting with Dr. Guirakhoo at the event, please email [email protected]. For more information about the event and to register, please visit the event website.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
